Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.70 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.61 |
| ▸ | STK4 | Q13043 | 1/20 | 0.59 |
| ▸ | STK3 | Q13188 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4962186 | 0.99 | EGFR (0.69) | EGFRERBB2ERBB4STK4STK3 | |
| SCHEMBL2951299 | 0.93 | EGFR (0.63) | EGFRERBB2ERBB4 | |
| SCHEMBL3593176 | 0.92 | EGFR (0.60) | EGFRERBB2ERBB4 | |
| SCHEMBL2204648 | 0.91 | EGFR (0.72) | EGFRERBB2STK4STK3 | |
| Hydrochloric Acid SCHEMBL4964202 | 0.90 | EGFR (0.71) | EGFRERBB2STK4STK3 | |
| SCHEMBL23408974 | 0.88 | STK4 (0.68) | EGFRERBB2STK4STK3 | |
| SCHEMBL20395110 | 0.87 | EGFR (0.68) | EGFRERBB2ERBB4STK4STK3 | |
| SCHEMBL4965102 | 0.87 | EGFR (0.81) | EGFRERBB2ERBB4STK4STK3 | |
| SCHEMBL3605026 | 0.86 | EGFR (0.70) | EGFRERBB2ERBB4 | |
| SCHEMBL31661478 | 0.86 | STK3 (0.68) | EGFRERBB2ERBB4STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | claimed |
| CN-112759583-B | Quinoline derivative containing furyl and preparation method and application thereof | 河南省医药科学研究院 | 2022-10-11 | — | — | CN | disclosed |
| CN-112694439-B | Phenyl acrylamide quinoline derivative and preparation method and application thereof | 河南省医药科学研究院 | 2022-08-30 | — | — | CN | disclosed |
| CN-112625025-B | Pyridyl substituted quinoline derivative and its prepn and use | 河南省医药科学研究院 | 2022-03-29 | — | — | CN | disclosed |
| CN-112759583-A | Quinoline derivative containing furyl and preparation method and application thereof | 河南省医药科学研究院 | 2021-05-07 | — | — | CN | disclosed |
| CN-112694439-A | Phenyl acrylamide quinoline derivative and preparation method and application thereof | 河南省医药科学研究院 | 2021-04-23 | — | — | CN | disclosed |
| CN-112625025-A | Pyridyl substituted quinoline derivative and its prepn and use | 河南省医药科学研究院 | 2021-04-09 | — | — | CN | disclosed |
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| EP-1883621-A2 | METHODS OF PREPARING 3-CYANO-QUINOLINES AND INTERMEDIATES MADE THEREBY | Wyeth (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1883631-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | Wyeth (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006127207-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270669-A1 | Method of preparing 3-cyano-quinolines and intermediates made thereby | WYETH | 2006-11-30 | — | — | US | disclosed |
| WO-2006127205-A2 | METHODS OF PREPARING 3-CYANO-QUINOLINES AND INTERMEDIATES MADE THEREBY | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | EGFR, BRCA1, PTPRJ | EGFR 1/4885ERBB2 5/4885ERBB4 9/4885 |
| US-20060270669-A1 | Method of preparing 3-cyano-quinolines and intermediates made thereby | CNP, PPP4C, PTMS | EGFR 3894/4885ERBB2 2020/4885ERBB4 973/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | EGFR 6/4885ERBB2 2/4885ERBB4 8/4885 |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | HCCS, CYP3A7, QPCT | EGFR 4068/4885ERBB2 3200/4885ERBB4 3148/4885 |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | EGFR, BRCA1, PTPRJ | EGFR 1/4885ERBB2 5/4885ERBB4 9/4885 |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885ERBB4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.